Early Anti-TNF Therapy Helps Reduce Health Care Utilization in Crohn Disease
Researchers compared the difference in overall health care utilization in patients with IBD who started anti-TNF therapy 2 years vs more than 2 years postdiagnosis.
Researchers compared the difference in overall health care utilization in patients with IBD who started anti-TNF therapy 2 years vs more than 2 years postdiagnosis.
The incidence of Crohn disease is increasing in the US. Experts outline the risk factors, pathophysiology, and symptoms of Crohn disease as well as strategies for diagnosis and treatment of this disease in the primary care setting.
Investigators assessed rates of symptoms of distress in parents of children with inflammatory bowel diseases and how the rates change over the child’s disease course.
Investigators assessed rates of psychiatric comorbidities and suicide, as well as their risk factors, in patients with childhood-onset immune-mediated inflammatory diseases.
Investigators assessed the association between processed meat consumption and risk for mortality among patients with inflammatory bowel disease.
Investigators assessed the efficacy and clinical effects of ustekinumab in patients with Crohn disease who had a previously failed anti-TNF therapy attempt.
After mRNA COVID-19 vaccination, 99% of patients with IBD had detectable antibodies regardless of immunocompromising therapies.
Measure indicating greater activity of IBD independently linked to ICU/ventilation/death and hospitalization among patients 50 years or younger.
Investigators assessed the efficacy of a machine learning tool that predicts steroid-free clinical remission in patients with ulcerative colitis receiving vedolizumab therapy.
Reviewing a patient’s potential risk for osteoporosis should be a routine part of each visit for patients with IBD.